Gene: HSP90AB1 | Protein: HSP90AB1 (Heat Shock Protein 90 Beta Family Member 1) | Aliases: HSP90B, HSP86, Hsp84, Hsp90, Hsp90-β
The HSP90AB1 gene encodes HSP90AB1 (Heat Shock Protein 90 Beta Family Member 1), a member of the heat shock protein 90 (Hsp90) family of molecular chaperones. As a essential molecular chaperone, HSP90AB1 plays critical roles in protein folding, stability, and function, particularly for client proteins involved in signal transduction, cell cycle control, and stress response [1].
HSP90AB1 is one of the most abundant proteins in the cell, comprising 1-2% of total cellular protein. It is essential for cellular viability and has emerged as an important therapeutic target in cancer and neurodegenerative diseases. The protein is highly conserved across eukaryotes, reflecting its fundamental cellular functions.
¶ Gene Structure and Expression
The HSP90AB1 gene is located on chromosome 6p21.1 in humans, within the major histocompatibility complex (MHC) class III region. This locus also contains other heat shock proteins including HSP90AA1.
The HSP90AB1 promoter contains several regulatory elements:
- HSE (Heat Shock Element): Multiple HSEs allow heat shock-induced transcription
- GC-rich regions: Multiple Sp1 binding sites for constitutive expression
- TATA box: Present but not essential for expression
- Intron/exon structure: 11 exons encoding the functional protein
HSP90AB1 produces multiple transcript variants:
- Variant 1 (canonical): Full-length protein encoding the predominant isoform
- Variant 2: Alternative splicing in 5'UTR affecting translation efficiency
- Isoforms: Multiple N-terminal isoforms with tissue-specific expression
HSP90AB1 is ubiquitously expressed at high levels:
- Brain: Particularly high in neurons, especially in synapses
- Liver: High expression in hepatocytes
- Muscle: Abundant in skeletal and cardiac muscle
- Immune cells: High expression in activated lymphocytes
¶ Protein Structure and Biochemistry
¶ Domain Architecture
HSP90AB1 is a 724-amino acid dimeric protein with distinct domains:
flowchart TD
A["N-terminus<br/>1-230 aa"] --> B["Middle domain<br/>231-600 aa"]
B --> C["C-terminus<br/>601-724 aa"]
A --> D["ATP binding site"]
B --> E["Client protein binding"]
C --> F["Dimerization<br/>Co-chaperone binding"]
¶ Structural Domains
-
N-terminal domain (1-230 aa):
- Contains the ATP-binding pocket
- Binds ATP and ADP
- Site for geldanamycin and other Hsp90 inhibitors
-
Middle domain (231-600 aa):
- Contains the client protein binding site
- Interacts with protein substrates
- Contains the catalytic site for ATP hydrolysis
-
C-terminal domain (601-724 aa):
- Mediates dimerization
- Contains the EEVD motif for co-chaperone binding
- Site for post-translational modifications
HSP90AB1 functions as a homodimer:
- Each monomer contains the three domains described above
- Dimerization occurs through C-terminal interactions
- The dimer creates a molecular "clamp" for client proteins
- Conformational changes during the ATPase cycle
HSP90AB1 undergoes extensive post-translational modifications:
-
Phosphorylation: Multiple serine/threonine phosphorylation sites
- Tyr-124 phosphorylation affects client binding
- Ser-231 and Ser-263 are regulatory sites
-
Acetylation: Lysine acetylation regulates function
- Lys-294 acetylation affects ATPase activity
- Lys-546 acetylation influences co-chaperone interactions
-
Sumoylation: SUMO modification affects stability
-
Ubiquitination: Regulates degradation
-
Nitrosylation: Affects chaperone function under stress
HSP90AB1 undergoes conformational changes during its ATPase cycle:
- Open state: Apo-Hsp90, client protein binding
- Closed state: ATP binding, client protein encapsulation
- Hydrolysis: ATP hydrolysis drives conformational changes
- Release: ADP release, client release
HSP90AB1 serves as a molecular chaperone:
- Protein folding: Assists in proper protein folding
- Stabilization: Prevents aggregation of misfolded proteins
- Complex assembly: Facilitates assembly of multi-protein complexes
- Quality control: Targets damaged proteins for degradation
HSP90AB1 interacts with hundreds of client proteins:
| Category |
Client Proteins |
Function |
| Kinases |
AKT, RAF, SRC |
Signal transduction |
| Steroid receptors |
ER, PR, AR |
Hormone signaling |
| Transcription factors |
p53, HIF-1α |
Gene regulation |
| Cell cycle |
CDK4, CDK6 |
Cell cycle control |
| Chaperones |
HSP70, HSP40 |
Protein folding |
HSP90AB1 is central to cellular protein quality control:
- Folding assistance: Helps proteins achieve native conformation
- Aggregate prevention: Prevents toxic protein aggregation
- Degradation targeting: Works with E3 ubiquitin ligases for degradation
- Stress response: Critical for surviving proteotoxic stress
In Alzheimer's disease, HSP90AB1 plays complex roles:
-
Tau Pathology: HSP90AB1 is involved in tau folding and aggregation
- Modulates tau phosphorylation through client kinases
- Can be recruited to neurofibrillary tangles
- Therapeutic targeting may reduce tau pathology
-
Amyloid-β Handling: HSP90AB1 affects Aβ production and clearance
- Client proteins include γ-secretase components
- Chaperone activity can reduce Aβ toxicity
- HSP90 inhibitors show promise in AD models
-
Synaptic Function: Essential for synaptic protein maintenance
- HSP90 is required for synaptic vesicle cycling
- Local translation at synapses requires HSP90
- Loss of HSP90 affects long-term potentiation
-
Therapeutic Targeting:
- HSP90 inhibitors reduce AD pathology in models
- 17-AAG (tanespimycin) has been studied in clinical trials
- Combination approaches show enhanced effects
HSP90AB1 is particularly relevant to Parkinson's disease:
-
Alpha-Synuclein: HSP90AB1 interacts with α-synuclein (SNCA)
- Modulates aggregation propensity
- Can target mutant SNCA for degradation
- HSP90 inhibition reduces aggregation
-
Parkin Function: HSP90AB1 is a co-chaperone for parkin (PRNK)
- Essential for parkin E3 ligase activity
- Mutations affecting this interaction contribute to PD
- Therapeutic modulation is under investigation
-
Dopaminergic Neuron Survival:
- HSP90 protects dopaminergic neurons from stress
- Client proteins include key survival factors
- Targeting HSP90 shows neuroprotective effects
-
LRRK2: HSP90AB1 is a client for LRRK2
- LRRK2 mutations common in familial PD
- HSP90 inhibition affects LRRK2 stability
- Therapeutic implications are being explored
-
SOD1: HSP90AB1 interacts with mutant SOD1
- Mutant SOD1 is a HSP90 client protein
- HSP90 inhibitors accelerate mutant SOD1 degradation
- Shows therapeutic potential in ALS models
-
FUS and TDP-43: HSP90AB1 affects ALS-associated proteins
- HSP90 inhibitors reduce toxicity
- Both FUS and TDP-43 are HSP90 clients
-
Motor Neuron Protection:
- HSP90 induction is neuroprotective
- Heat shock response is impaired in ALS
- Therapeutic approaches targeting HSP90 are promising
-
Mutant Huntingtin: HSP90AB1 binds mutant Htt
- Contributes to aggregation
- HSP90 inhibition reduces aggregation
- Client proteins include kinases affecting Htt toxicity
-
Therapeutic Targeting:
- HSP90 inhibitors show benefits in HD models
- Reduce mutant Htt aggregation
- Improve motor function in models
| Disease |
HSP90AB1 Role |
| Prion Disease |
Prion protein chaperone |
| Frontotemporal Dementia |
TDP-43 and FUS clients |
| Multiple Sclerosis |
Myelin protein folding |
| Spinocerebellar Ataxia |
Polyglutamine client |
HSP90 inhibitors have been extensively studied:
-
Geldanamycin derivatives:
- 17-AAG (tanespimycin)
- 17-DMAG (alvespimycin)
- Retaspimycin (IPI-504)
-
Synthetic inhibitors:
- PU-H71
- NVP-HSP990
- AT13387
-
Natural compounds:
| Compound |
Condition |
Status |
| Tanespimycin |
Alzheimer's Disease |
Phase 1/2 completed |
| PU-H71 |
Parkinson's Disease |
Preclinical |
| Geldanamycin derivatives |
ALS |
Preclinical |
- Cancer effects: HSP90 inhibitors have anti-cancer effects
- CNS penetration: Many inhibitors have poor brain penetration
- Toxicity: Off-target effects and toxicity issues
- Client protein diversity: Broad client protein network
HSP90AB1 interacts with multiple co-chaperones:
| Co-chaperone |
Function |
| HOP |
Client protein transfer |
| CDC37 |
Kinase client recruitment |
| AHA1 |
ATPase stimulation |
| p23 |
Client protein folding |
| HSP70 |
Cooperative chaperone |
| FKBP4/5 |
Immunophilin client binding |
| PP5 |
Dephosphorylation |
flowchart LR
HSP90["HSP90AB1"] -->|"bind"| CDC37["CDC37"]
HSP90 -->|"bind"| HOP["HOP"]
HSP90 -->|"bind"| AHA1["AHA1"]
HSP90 -->|"bind"| p23["p23"]
CDC37 -->|"recruit"| KIN["Kinases"]
HOP -->|"transfer"| HSP70["HSP70"]
KIN -->|"signaling"| PATH["Pathways"]
HSP90AB1 polymorphisms have been studied:
- Promoter polymorphisms: Affect expression levels
- Coding polymorphisms: May affect client protein interactions
- Disease associations: Some variants linked to neurodegeneration risk
HSP90AB1 expression is epigenetically regulated:
- Promoter methylation: Can silence expression
- Histone modifications: Affect transcription
- Age-related changes: Expression changes with aging
- Hsp90ab1 knockout: Embryonic lethal in mice
- Conditional knockout: Reveals tissue-specific functions
- Neuron-specific knockout: Shows neuronal phenotypes
- HSP90 overexpression: Protective in neurodegeneration models
- Mutant client proteins: Model various diseases
-
Extracellular HSP90: Released from cells under stress
- Blood levels indicate cellular stress
- Potential biomarker for neurodegeneration
-
HSP90 complexes: Different client-bound complexes
- Indicate specific pathway activation
- May have diagnostic value
HSP90AB1 is part of the protein quality control network:
- Works with HSP70/HSP40 for protein folding
- Links to ubiquitin-proteasome system
- Intersects with autophagy pathway
- Essential for maintaining proteostasis
| Protein |
Interaction |
| SNCA |
Modulates aggregation |
| PARK2 |
Parkin co-chaperone |
| LRRK2 |
LRRK2 client |
| MAPT |
Tau kinase client |
| SOD1 |
Mutant SOD1 client |
| TARDBP |
TDP-43 interaction |
HSP90AB1 is essential for synaptic function:
- Required for AMPA receptor trafficking
- Essential for NMDA receptor function
- Involved in synaptic vesicle cycling
- Critical for learning and memory
HSP90AB1 participates in axonal transport:
- Client proteins include motor proteins
- Required for organelle transport
- Axonal protection under stress
The heat shock response is neuroprotective:
- HSP90 induction protects neurons
- Transcriptional regulation via HSF1
- Declines with age
HSP90 is highly conserved:
- Yeast: Essential for viability
- Drosophila: Essential for development
- Zebrafish: Brain development requires HSP90
- Mice: Embryonic lethal knockout
- Next-generation inhibitors: Improved specificity and brain penetration
- Co-chaperone targeting: More selective modulation
- Combination therapies: With other neuroprotective agents
- How does HSP90 client specificity change in disease?
- Can we develop neuron-specific HSP90 modulators?
- What determines client protein selection?
- How does HSP90 interact with aging?
HSP90AB1 is an essential molecular chaperone with critical roles in protein folding, stability, and cellular proteostasis. In neurodegenerative diseases, HSP90AB1 interacts with disease-associated proteins including α-synuclein, tau, mutant SOD1, and parkin. Therapeutic modulation of HSP90AB1 represents a promising approach for treating AD, PD, ALS, and related conditions. The protein's central role in maintaining cellular proteostasis makes it an attractive target for neuroprotective strategies.
- Taipale et al., HSP90: the crucial hub of the HSP90 network (2010) (2010)
- Pratt et al., The HSP90-based client protein interaction network (2010) (2010)
- Luo et al., HSP90 and neurodegeneration (2019) (2019)
- Unknown, Tatu and Helenius, HSP90 and protein quality control (2019) (2019)
- Wang et al., HSP90 inhibitors in Alzheimer's disease (2020) (2020)